Summit Therapeu ADR (SMMT)

$17.00 +0.38 (2.29%)
Market Cap 12.90B
Revenue (ttm) 0.00
Net Income (ttm) -1.08B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 5,259,900
Avg Vol 3,922,144
Day's Range N/A - N/A
Shares Out 776.16M
Stochastic %K 41%
Beta -1.25
Analysts Sell
Price Target $30.86

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical...

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
MedicineMan777
MedicineMan777 May. 27 at 2:36 PM
$SMMT too little too late, Merk has a better drug combination with 65% os compares to summits 45% OS
1 · Reply
Reneejordan001
Reneejordan001 May. 27 at 1:35 PM
$SMMT No one gets these slots to present at the biggest biotech conference if you don't have the goods. 👇🤞👌💞
1 · Reply
EB2224
EB2224 May. 27 at 1:23 PM
$SMMT starting coverage right before ASCO while they are in a blackout and the company can’t respond is certainly a choice isn’t it…not suspect at all
0 · Reply
MedicineMan777
MedicineMan777 May. 27 at 12:22 PM
$SMMT Bernstein initiated coverage of the Miami, Florida-based biotech with an Underperform rating and $7.70 price target on Thursday. H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy, citing overhang from a new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck (MRK) in partnership with Chinese company Kelun-Biotech.
0 · Reply
coocookyky
coocookyky May. 27 at 10:35 AM
Brothers of Rome… the weak flee at the first sight of red candles. But we? We stand shield to shield. $SMMT is not merely a stock… it is our campaign. Every dip is another battlefield. Every doubter, another barbarian at the gates. The market wishes to test our resolve. Let it. For fortunes were never forged by peasants hiding in fear — they were claimed by warriors with diamond hands and iron conviction. When the historians speak of this age, they will not remember the cowards who sold for scraps… They will remember the legion that HELD. Raise the banners. Tighten formation. Rome was not built in a day — and neither is generational wealth. AVE SMMT ⚔️📈
0 · Reply
TruthBroker2
TruthBroker2 May. 26 at 10:20 PM
$SMMT 👍
0 · Reply
LeisureSuitLarry
LeisureSuitLarry May. 26 at 7:46 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 May. 26 at 4:27 PM
$SMMT #1
0 · Reply
officialshawn
officialshawn May. 26 at 3:46 PM
$SMMT this is where things get interesting.
1 · Reply
RunFYLife
RunFYLife May. 26 at 3:34 PM
$SMMT
0 · Reply
Latest News on SMMT
Summit Therapeutics management to meet with Cantor

2026-05-26T21:01:32.000Z - 17 hours ago

Summit Therapeutics management to meet with Cantor

Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-05-22T10:16:33.000Z - 5 days ago

Summit Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

Bernstein starts Summit with an Underperform, says ‘not on solid footing’

2026-05-21T21:26:44.000Z - 5 days ago

Bernstein starts Summit with an Underperform, says ‘not on solid footing’

Summit Therapeutics initiated with an Underperform at Bernstein

2026-05-21T20:28:05.000Z - 5 days ago

Summit Therapeutics initiated with an Underperform at Bernstein

3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22

2026-05-18T20:12:08.000Z - 8 days ago

3 Best Stocks to Buy This Week, According to Analysts – May 18-May 22

BSX ZETA

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

May 4, 2026, 9:23 AM EDT - 23 days ago

Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright

2026-05-04T10:22:41.000Z - 23 days ago

Summit Therapeutics price target lowered to $23 from $30 at H.C. Wainwright

Summit Therapeutics falls -23.7%

2026-05-01T16:04:50.000Z - 25 days ago

Summit Therapeutics falls -23.7%

Summit Therapeutics falls -27.4%

2026-05-01T14:55:38.000Z - 25 days ago

Summit Therapeutics falls -27.4%

Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler

2026-05-01T11:33:37.000Z - 26 days ago

Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler

Summit Therapeutics price target lowered to $31 from $32 at Clear Street

2026-04-30T23:55:23.000Z - 26 days ago

Summit Therapeutics price target lowered to $31 from $32 at Clear Street

Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)

2026-04-30T20:53:09.000Z - 26 days ago

Summit Therapeutics reports Q1 adjusted EPS (15c), consensus (21c)

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Apr 30, 2026, 4:32 PM EDT - 26 days ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Summit Therapeutics Earnings release: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 26 days ago

Summit Therapeutics Earnings release: Q1 2026

Summit Therapeutics Quarterly report: Q1 2026

Apr 30, 2026, 4:00 PM EDT - 26 days ago

Summit Therapeutics Quarterly report: Q1 2026

Summit Therapeutics options imply 7.3% move in share price post-earnings

2026-04-30T19:29:07.000Z - 26 days ago

Summit Therapeutics options imply 7.3% move in share price post-earnings

Summit Therapeutics put volume heavy and directionally bearish

2026-04-23T14:55:17.000Z - 4 weeks ago

Summit Therapeutics put volume heavy and directionally bearish

Summit partner selection for ASCO plenary signals strong OS, says Leerink

2026-04-21T17:15:44.000Z - 5 weeks ago

Summit partner selection for ASCO plenary signals strong OS, says Leerink

BNTX

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

2026-04-21T16:09:04.000Z - 5 weeks ago

Summit partner selection for ASCO ‘likely a major positive,’ says Guggenheim

Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 weeks ago

Summit Therapeutics Proxy statement: Proxy filing

Summit Therapeutics Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 5 weeks ago

Summit Therapeutics Proxy statement: Proxy filing

Summit Therapeutics Proxy statement: Proxy filing

Apr 6, 2026, 8:00 AM EDT - 7 weeks ago

Summit Therapeutics Proxy statement: Proxy filing

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Mar 27, 2026, 8:15 AM EDT - 2 months ago

Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 2:15 PM EDT - 2 months ago

Summit Therapeutics Transcript: The Citizens Life Sciences Conference 2026

Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 2:30 PM EST - 3 months ago

Summit Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Summit Therapeutics to Present at Upcoming Investor Conferences

Feb 26, 2026, 6:45 PM EST - 3 months ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Earnings Call Transcript: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

Summit Therapeutics Earnings Call Transcript: Q4 2025

Summit Therapeutics Annual report: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

Summit Therapeutics Annual report: Q4 2025

Summit Therapeutics Earnings release: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

Summit Therapeutics Earnings release: Q4 2025

Summit Therapeutics Slides: Q4 2025

Feb 23, 2026, 4:30 PM EST - 3 months ago

Summit Therapeutics Slides: Q4 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Feb 23, 2026, 4:05 PM EST - 3 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Feb 17, 2026, 5:05 PM EST - 3 months ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 30, 2026, 4:30 PM EST - 4 months ago

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Jan 29, 2026, 7:30 AM EST - 4 months ago

Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy

Summit Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:45 PM EST - 4 months ago

Summit Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 12:45 PM EST - 4 months ago

Summit Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

Jan 12, 2026, 6:15 AM EST - 4 months ago

Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)

GSK

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Jan 12, 2026, 6:00 AM EST - 4 months ago

Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 7:30 AM EST - 5 months ago

Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 2:10 PM EST - 6 months ago

Summit Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Summit Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 10:30 AM EST - 6 months ago

Summit Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Summit Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 10:30 AM EST - 6 months ago

Summit Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Summit Therapeutics Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 3:30 PM EST - 7 months ago

Summit Therapeutics Transcript: UBS Global Healthcare Conference 2025

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Nov 7, 2025, 9:00 AM EST - 7 months ago

Ivonescimab Plus Chemotherapy Demonstrates a Statistically Significant Benefit in Overall Survival with a Hazard Ratio of 0.74 in 2L+ Treatment of Patients with EGFRm NSCLC in HARMONi-A Study Conducted by Akeso in China

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Oct 31, 2025, 7:00 AM EDT - 7 months ago

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Why Wall Street Is Backing These 3 Comeback Stocks

Oct 28, 2025, 6:44 PM EDT - 7 months ago

Why Wall Street Is Backing These 3 Comeback Stocks

SFM TTD

Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Summit Therapeutics Raises $500 Million in Private Placement

Summit Therapeutics Earnings Call Transcript: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Summit Therapeutics Earnings Call Transcript: Q3 2025

Summit Therapeutics Earnings release: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Summit Therapeutics Earnings release: Q3 2025

Summit Therapeutics Quarterly report: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Summit Therapeutics Quarterly report: Q3 2025

Summit Therapeutics Slides: Q3 2025

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Summit Therapeutics Slides: Q3 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Oct 20, 2025, 6:45 AM EDT - 7 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2025

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Oct 19, 2025, 10:30 AM EDT - 7 months ago

Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Oct 17, 2025, 7:00 AM EDT - 7 months ago

Summit Therapeutics Announces Expansion of Ivonescimab Global Phase III Development Program with HARMONi-GI3 Study in 1L Colorectal Cancer

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Oct 15, 2025, 7:00 AM EDT - 8 months ago

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Sep 24, 2025, 7:00 AM EDT - 8 months ago

HARMONi-6, Featuring Ivonescimab Combined with Chemotherapy vs. Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in China, to be Showcased in Presidential Symposium at ESMO 2025

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Sep 17, 2025, 10:54 PM EDT - 8 months ago

Summit Therapeutics: Buy the Next Dip Amid Clinical Breakthrough Potential

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 9 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 10, 2025, 12:43 AM EDT - 9 months ago

CORRECTION -- Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Summit Therapeutics Transcript: Study Update

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Transcript: Study Update

Summit Therapeutics Press release: Study Update

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Press release: Study Update

Summit Therapeutics Slides: Study Update

Sep 8, 2025, 8:00 AM EDT - 9 months ago

Summit Therapeutics Slides: Study Update

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Sep 7, 2025, 6:08 AM EDT - 9 months ago

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Sep 7, 2025, 3:30 AM EDT - 9 months ago

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Sep 3, 2025, 7:00 AM EDT - 9 months ago

Summit Therapeutics to Host Update Call at WCLC 2025 on September 8, 2025

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Aug 14, 2025, 7:00 AM EDT - 10 months ago

Ivonescimab Data from Global Phase III HARMONi Study to be Showcased at Presidential Symposium at WCLC 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Aug 11, 2025, 5:03 PM EDT - 10 months ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2025

Summit Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Summit Therapeutics Earnings release: Q2 2025

Summit Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 7:00 AM EDT - 10 months ago

Summit Therapeutics Quarterly report: Q2 2025

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

Jun 30, 2025, 8:00 AM EDT - 11 months ago

Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors

RVMD

Summit Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 9, 2025, 1:20 PM EDT - 1 year ago

Summit Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Is SMMT Stock A Buy After Its Recent Plunge?

Jun 2, 2025, 9:10 AM EDT - 1 year ago

Is SMMT Stock A Buy After Its Recent Plunge?

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

May 30, 2025, 9:27 AM EDT - 1 year ago

Summit Therapeutics Study Is a Win for China Biopharma Deals. Why the Stock Is Down.

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

May 30, 2025, 6:00 AM EDT - 1 year ago

Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

Final Trade: NVS, XLU and SMMT

May 1, 2025, 6:20 PM EDT - 1 year ago

Final Trade: NVS, XLU and SMMT

NVS XLU

Summit Therapeutics Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Earnings Call Transcript: Q1 2025

Summit Therapeutics Quarterly report: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Quarterly report: Q1 2025

Summit Therapeutics Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Earnings release: Q1 2025

Summit Therapeutics Slides: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Summit Therapeutics Slides: Q1 2025

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

May 1, 2025, 4:09 PM EDT - 1 year ago

Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

Summit Therapeutics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Summit Therapeutics Proxy statement: Proxy Filing

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Apr 25, 2025, 2:50 PM EDT - 1 year ago

Interim Overall Survival Analysis Requested from Chinese Health Authorities Shows a Clinically Meaningful, Positive Trend Favoring Ivonescimab Compared to Pembrolizumab in PD-L1 Positive Advanced NSCLC from HARMONi-2 Study Conducted by Akeso in China

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Apr 23, 2025, 6:15 AM EDT - 1 year ago

Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Mar 17, 2025, 4:24 PM EDT - 1 year ago

Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

Feb 24, 2025, 8:13 PM EST - 1 year ago

Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs

PFE

Summit Therapeutics Earnings Call Transcript: Q4 2024

Feb 24, 2025, 9:00 AM EST - 1 year ago

Summit Therapeutics Earnings Call Transcript: Q4 2024

Summit Therapeutics Annual report: Q4 2024

Feb 24, 2025, 9:00 AM EST - 1 year ago

Summit Therapeutics Annual report: Q4 2024

Summit Therapeutics Earnings release: Q4 2024

Feb 24, 2025, 9:00 AM EST - 1 year ago

Summit Therapeutics Earnings release: Q4 2024

Summit Therapeutics Slides: Q4 2024

Feb 24, 2025, 9:00 AM EST - 1 year ago

Summit Therapeutics Slides: Q4 2024

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Feb 24, 2025, 6:05 AM EST - 1 year ago

Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

Feb 24, 2025, 6:00 AM EST - 1 year ago

Summit Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Ivonescimab in Combination with Pfizer Antibody Drug Conjugates (ADCs)

PFE

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Feb 18, 2025, 9:00 AM EST - 1 year ago

Summit Therapeutics to Host Fourth Quarter and Full Year 2024 Financial Results & Operational Progress Call on February 24, 2025

Summit Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

Summit Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Summit Therapeutics Slides: FY 2025

Jan 13, 2025, 6:00 PM EST - 1 year ago

Summit Therapeutics Slides: FY 2025

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 1 year ago

Summit Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Summit Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Dec 4, 2024, 8:45 AM EST - 1 year ago

Summit Therapeutics Transcript: Citi's 2024 Global Healthcare Conference

Summit Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Dec 3, 2024, 8:45 AM EST - 1 year ago

Summit Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?

Nov 4, 2024, 10:00 AM EST - 1 year ago

Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?

MedicineMan777
MedicineMan777 May. 27 at 2:36 PM
$SMMT too little too late, Merk has a better drug combination with 65% os compares to summits 45% OS
1 · Reply
Reneejordan001
Reneejordan001 May. 27 at 1:35 PM
$SMMT No one gets these slots to present at the biggest biotech conference if you don't have the goods. 👇🤞👌💞
1 · Reply
EB2224
EB2224 May. 27 at 1:23 PM
$SMMT starting coverage right before ASCO while they are in a blackout and the company can’t respond is certainly a choice isn’t it…not suspect at all
0 · Reply
MedicineMan777
MedicineMan777 May. 27 at 12:22 PM
$SMMT Bernstein initiated coverage of the Miami, Florida-based biotech with an Underperform rating and $7.70 price target on Thursday. H.C. Wainwright downgraded Summit Therapeutics (SMMT) to Neutral from Buy, citing overhang from a new late-stage trial readout for sac-TMT, a lung cancer therapy developed by Merck (MRK) in partnership with Chinese company Kelun-Biotech.
0 · Reply
coocookyky
coocookyky May. 27 at 10:35 AM
Brothers of Rome… the weak flee at the first sight of red candles. But we? We stand shield to shield. $SMMT is not merely a stock… it is our campaign. Every dip is another battlefield. Every doubter, another barbarian at the gates. The market wishes to test our resolve. Let it. For fortunes were never forged by peasants hiding in fear — they were claimed by warriors with diamond hands and iron conviction. When the historians speak of this age, they will not remember the cowards who sold for scraps… They will remember the legion that HELD. Raise the banners. Tighten formation. Rome was not built in a day — and neither is generational wealth. AVE SMMT ⚔️📈
0 · Reply
TruthBroker2
TruthBroker2 May. 26 at 10:20 PM
$SMMT 👍
0 · Reply
LeisureSuitLarry
LeisureSuitLarry May. 26 at 7:46 PM
$SMMT
0 · Reply
TruthBroker2
TruthBroker2 May. 26 at 4:27 PM
$SMMT #1
0 · Reply
officialshawn
officialshawn May. 26 at 3:46 PM
$SMMT this is where things get interesting.
1 · Reply
RunFYLife
RunFYLife May. 26 at 3:34 PM
$SMMT
0 · Reply
coocookyky
coocookyky May. 26 at 12:02 PM
$SMMT SMMT$ IS NOT JUST A STOCK. IT’S A LOADING SCREEN FOR A DIFFERENT LIFE. While everybody else is chasing dead plays and panic selling every dip, the smart money is staring straight at Summit Therapeutics. The market still hasn’t fully realized what’s sitting in front of it. Massive biotech upside. Insane volatility. The kind of setup that turns normal accounts into legendary screenshots. People laughed at Tesla early. People ignored NVDA early. Every monster run starts with doubt. This isn’t financial advice. This is conviction. The risk? Real. But the reward? Potentially life changing. You either watch SMMT from the sidelines while others print… or you load up before the crowd realizes what’s happening. Weak hands check price every hour. Strong hands check the future. SMMT$ TO THE MOON 🚀
1 · Reply
TruthBroker2
TruthBroker2 May. 26 at 9:53 AM
$SMMT $PLSE .
0 · Reply
SmokeWagon
SmokeWagon May. 25 at 8:58 PM
$SMMT 6 Days. Better get yourself right. IMO it’ll never turn back from that point.
1 · Reply
Teluride
Teluride May. 24 at 6:48 PM
$SMMT / Akeso Timeline to Watch • Sunday, May 31, 2026 7:00 AM Central (8:00 AM Eastern) ASCO releases the Late-Breaking Abstract for HARMONi-6 — first public release of the OS hazard ratio and detailed data. • Sunday Afternoon, May 31, 2026 Approximately 1:47 PM Central Time Akeso presents the HARMONi-6 plenary session at ASCO 2026. This is one of the most prestigious presentation slots in oncology. • Monday, June 1, 2026 6:00 AM Central (7:00 AM Eastern) Summit Therapeutics (https://www.smmttx.com?utm_source=chatgpt.com) company update and investor conference call following the ASCO plenary presentation.
1 · Reply
TruthBroker2
TruthBroker2 May. 23 at 6:10 PM
$SMMT 👍
0 · Reply
Carl81
Carl81 May. 23 at 1:01 PM
$SMMT .
0 · Reply
BapoRothstein
BapoRothstein May. 22 at 10:01 PM
$SMMT Some bum analyst no one ever heard of is bearish. Meanwhile, Bob Duggan, Baker Bros, and ASCO, with real skin in the game, are acting with the strong belief that this company is likely to change the course of medical practice and history.
2 · Reply
HitstheGreen
HitstheGreen May. 22 at 7:42 PM
$SMMT db my shrs
0 · Reply
TruthBroker2
TruthBroker2 May. 22 at 5:54 PM
$SMMT .
0 · Reply
Reneejordan001
Reneejordan001 May. 22 at 5:23 PM
$SMMT Either Merck is nervous about the results or they are in talks to buy us out and this downgrade was definitely done on purpose right before Bob Duggan presents the OS at one of the biggest conferences. Just something to ponder. We shall see
1 · Reply
LeisureSuitLarry
LeisureSuitLarry May. 22 at 3:12 PM
$SMMT
2 · Reply
TruthBroker2
TruthBroker2 May. 22 at 2:09 PM
$SMMT .
0 · Reply